PeerView Oncology CME/CNE/CPE Audio Podcast
Summary: PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
- Visit Website
- RSS
- Artist: PVI, PeerView Institute for Medical Education
- Copyright: 2007
Podcasts:
In this CME activity, an expert discusses treatment of advanced NSCLC, with a main focus on optimal integration of targeted agents into standard therapy for this disease.
Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.
In this CME activity, an expert discusses treatment of early stage HER2-positive breast cancer based on relevant case scenarios, with a main focus on optimal use of HER2-targeted therapy in the context of other available treatment options.
Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.
In this activity, experts present current data on antiangiogenic therapies in metastatic breast cancer (MBC). Clinical relevance of the endpoints used with cytostatic targeted agents and cytotoxic chemotherapeutics in MBC is evaluated. Recent efficacy and safety data from studies evaluating antiangiogenic therapies in advanced disease are summarized and interpreted, and practical recommendations for optimal integration of angiogenesis inhibitors into the treatment of MBC are provided.
In this activity, experts in the treatment of lung cancer present the most current data on molecularly targeted agents in the treatment of NSCLC. Efficacy and safety of anti-VEGF, anti-EGFR, and other novel targeted therapies will be discussed. The experts will also focus on the evolving role of predictive and prognostic markers and the importance of developing such tools that could assist clinicians in selecting optimal therapy for each individual patient with lung cancer.
In this program, experts present up-to-date information on treatment of advanced or metastatic NSCLC. Options for first-, second-, and third-line treatment are discussed, and factors that influence treatment decisions in these settings are assessed.
In this CME activity, experts in lung cancer discuss the current and evolving role of molecularly targeted therapies in NSCLC. Clinical data on anti-VEGF and anti-EGFR therapies are assessed, and practical considerations for optimal integration of these agents into standard treatment for NSCLC are discussed. Unanswered questions regarding the role of targeted therapies and future research directions are described as well.
In this CME activity, experts in the treatment of hepatocellular carcinoma (HCC) discuss recent data on the efficacy and safety of emerging biologically driven agents in this condition. The recent data on staging systems and classification systems for HCC are also reviewed and the molecular targets in HCC are discussed.
In this panel discussion, experts present up-to-date data on antiangiogenic therapies in breast cancer. Recent clinical data on antiangiogenic therapy in metastatic breast cancer are reviewed, and implications for clinical practice and research are discussed. The potential benefits of targeting multiple pathways in breast cancer, by using a combination of antiangiogenic and other biologic agents or novel multitargeted therapies with antiangiogenic properties, are described. As well, strategies for optimal integration of antiangiogenic agents into treatment of breast cancer in the context of other cytotoxic and biologic therapies are discussed.
In this CME activity, experts in the treatment of advanced renal cell carcinoma discuss recent data on the efficacy and safety of current and emerging targeted agents and combinations in this condition. Dosing concerns and patient selection are also highlighted.
In this activity, experts present up-to-date data on molecularly targeted therapies in metastatic colorectal cancer (CRC). The impact and expanding role of targeted agents in the treatment of metastatic CRC are reviewed, and latest efficacy and safety data biologics in the context of other available therapies, as well as the potential implications for clinical practice, are assessed. Furthermore, important clinical questions/issues related to treatment of advanced disease are discussed, and strategies for optimal use of all the available agents in the treatment of patients with metastatic CRC are proposed.
In this CME activity, experts provide an overview of recent progress in the treatment of breast cancer, focusing on the evolving role of molecularly targeted therapies. Current clinical data on HER2- and VEGF-targeted agents in the treatment of early stage and metastatic breast cancer are summarized, and the clinical implications of these data are assessed. Furthermore, clinical issues related to optimal use of HER2- and VEGF-targeted therapies in the treatment of breast cancer are discussed. Lastly, some of the new and ongoing studies evaluating the targeted agents are reviewed, as well as novel molecularly targeted therapies currently under investigation in breast cancer.
In this CME activity, experts in the management of CML discuss current and emerging targeted therapies for this condition. Mechanisms for the development and monitoring of resistance are also reviewed.
